biotech-companies-new-41.html
Novo Annual Review 2016
42 / 71
novo
seeds in brief 2016
novo seeds vision is to create an even stronger nordic biotech industry. we do this by building and investing in startup companies, which are founded on great science and that develop products with the potential to transform patient treatment. seed companies pre-seeds projects novo seeds investments in dkk million value at the end of the year investments during the year cash proceeds during the year unrealised and realised returns during the year 291 2016 2015 250 129 75 26 -81 56 149 1 denmark acesion pharma
adenium biotech avilex pharma biosyntia hoba pharmaceuticals io biotech minervax nmd pharma reapplix antag antibiotx bioprotect childtreat dare diacure glyprovac glia isd-immunotec lox mirana noncodania reticare rsk inhibitors tonsl 2 sweden amra galecto biotech merozyne rspr pharma apoa-i derived peptides biopetrolia 3 finland forendo pharma pepticrad 4 norway zinchel 5 france corwave lysogene 6 switzerland inthera bioscience 7 germany heparegenix 8 uk macrophage pharma pre-seed grants seed investments 350 400 450 500 300 250 200 150 100 50 0 accumulated cost of pre-seed grants and investments (as of 31.12.16) pre-seed projects portfolio companies 2016 2015 2014 2013 2012 2011 2010 2009 2008 2016 2015 2014 2013 2012 2011 2010 2009 2008 30 40 50 20 10 accumulated number of pre-seed projects and portfolio companies (as of 31.12.16) 0 42 novo a/s 2016
seeds-novo-43.html
